Tessera Therapeutics

Writing a new future for medicine

Somerville, United States · Founded 2018 · $730.0M raised

Employees
201–500
Founded
2018
Business Model
B2B
Total Funding
$730.0M
Last Round
$150.0M Corporate RoundDec 2025
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Tessera Therapeutics is a Flagship Pioneering biotechnology company pioneering Gene Writing, a novel genome engineering platform that uses mobile genetic elements to make permanent, programmable changes to the human genome. Unlike CRISPR-based editing, Gene Writing can make small and large alterations without double-strand DNA breaks. The company is advancing in vivo programs for rare diseases including alpha-1 antitrypsin deficiency and sickle cell disease, with Regeneron as a key development partner.

Summary

Tessera Therapeutics is a Biotech company based in Somerville, United States, founded in 2018. It has raised $730.0M in total across 4 rounds, most recently a $150.0M Corporate Round in Dec 2025. Investors include Regeneron Pharmaceuticals, Bill & Melinda Gates Foundation and Abu Dhabi Investment Authority.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate Partnership InvestmentDec 2025
$150.0M

Sign up to see all 4 events

Funding: Series B through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
PacBioIPO

Developer and manufacturer of high-accuracy long-read DNA sequencing systems and consumables for ...

USA, United States501–1000Biotech, Genomics
ConvertibleTotal funding$1.2BFeb 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025
Element Biosciences

Life science company democratizing access to advanced DNA sequencing tools with high-quality, aff...

San Diego, United States201–500Biotech, Genomics
Series ETotal funding$853.3MJun 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tessera Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/tessera-therapeutics"><img src="https://indexed.vc/api/badge/company/tessera-therapeutics" alt="Tessera Therapeutics on Indexed.vc" width="260" height="76" /></a>